Rituximab is a chimeric human-mouse monoclonal anti-CD20 antibody initially developed to
treat B cell lymphoproliferative disorders (1). It is now increasingly being used for the …

Autoimmune blistering diseases are associated with autoantibodies to desmosomal
(pemphigus group) or hemidesmosomal proteins (autoimmune subepidermal blistering …

The aim of the treatment in autoimmune blistering diseases (AIBDs) is to induce and
maintain remission, which clinically corresponds to the cessation of new vesicle formation …

Background Bullous pemphigoid (BP) is the most common autoimmune blistering disease
requiring treatment with immunosuppressive medications; however, finding a therapy that …

We propose rituximab as a first-line therapy for pemphigus vulgaris and steroid-dependent
bullous pemphigoid with or without systemic steroids. A brief review of the literature …

The conventional treatment for the autoimmune bullous skin diseases is broad-spectrum
immunosuppressive regimen typically combining systemic corticosteroids with adjuvant …

BACKGROUND: Rituximab has been increasingly used in autoimmune blistering
dermatoses, mainly in pemphigus. However, only a few larger case series are available on …

Treatment of autoimmune blistering diseases consists of systemic glucocorticosteroids
usually in combination with additional immunosuppressants such as azathioprine and …

Rituximab is a chimeric monoclonal antibody that selectively binds to the CD20 molecule on
B cells, resulting in their lysis. In autoimmune blistering diseases, the auto-antibody …

Pemphigus is an autoimmune B‐cell mediated blistering disease associated with significant
morbidity and mortality. Rituximab has proven effective for the treatment of steroid‐refractory …